10-Q: IMAC Holdings Reports First Quarter 2024 Results Amid Strategic Shift
Quarterly Report
IMAC Holdings reports its first quarter 2024 results, reflecting the discontinuation of its clinic operations and a strategic shift towards new business ventures.
Summary
- IMAC Holdings has released its financial results for the first quarter of 2024, showing a net loss of $407,219.
- The company has discontinued all patient care operations at its locations as of March 31, 2024, and these operations are now classified as discontinued operations.
- There were no patient revenues for the quarter, compared to $2,093,362 in the same period last year.
- The company's operating expenses decreased significantly to $408,630 from $1,296,018 year-over-year, due to the closure of all locations.
- The company's working capital deficit was approximately $1.2 million as of March 31, 2024.
- IMAC Holdings is exploring strategic alternatives, including a merger or acquisition of a new business, to support future operations.
- The company has a note receivable of $731,067, but has recorded a credit loss allowance of $2.3 million against it due to the financial position of the borrower.
- The company has undergone significant changes in its capital structure, including the issuance of new series of preferred stock and warrants.
Sentiment
Score: 2
Explanation: The sentiment is very negative due to the discontinuation of operations, significant losses, and the company's going concern issues. The strategic shift and capital raising efforts are not enough to offset the negative financial situation.
Positives
- Operating expenses decreased significantly due to the closure of all locations, which may help reduce cash burn.
- The company is actively exploring strategic alternatives, including a merger or acquisition, to support future operations.
- The company has restructured its capital through the issuance of new preferred stock and warrants.
Negatives
- The company has discontinued all patient care operations, resulting in no revenue for the quarter.
- The company has a significant working capital deficit of approximately $1.2 million.
- The company has recorded a substantial credit loss allowance against a note receivable, indicating potential losses.
- The company has an accumulated deficit of $56.3 million.
- The company's management has determined that its financial condition raises substantial doubt about its ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is in doubt due to substantial losses and a working capital deficit.
- The company may be unable to raise additional capital to fund future operations.
- The company's strategic alternatives, including a merger or acquisition, may not be successful.
- The company faces risks related to the integration of Theralink's assets and liabilities.
- The company's internal controls over financial reporting are not effective due to material weaknesses.
Future Outlook
The company is focused on exploring strategic alternatives, including a merger or acquisition of a new business, to support future operations. The company has also acquired the assets of Theralink Technologies and is working to integrate them into its operations.
Management Comments
- Management recognizes that the Company may need to obtain additional resources to successfully implement its business plans.
- Management has been actively exploring various strategic alternatives in an effort to support operations in 2024 and beyond.
Industry Context
The company's shift away from direct patient care and towards strategic alternatives reflects a challenging environment for healthcare providers, particularly those focused on non-surgical treatments. The company's move to acquire Theralink's assets and explore new business ventures is a response to these challenges.
Comparison to Industry Standards
- It is difficult to compare IMAC's results to industry standards due to the discontinuation of its core operations.
- The company's financial performance is significantly below industry benchmarks for healthcare providers with ongoing operations.
- The company's strategic shift is not typical for established healthcare providers, but may be necessary given its financial challenges.
- The company's decision to acquire Theralink's assets is a unique situation and does not have a direct industry comparison.
Legal Proceedings
- The company is involved in ongoing appeals related to Medicare overpayment claims.
Stakeholder Impact
- Shareholders are negatively impacted by the company's poor financial performance and going concern issues.
- Employees are impacted by the discontinuation of operations and the restructuring of the company.
- Customers are impacted by the closure of all patient care locations.
Next Steps
- The company will continue to explore strategic alternatives, including a merger or acquisition.
- The company will work to integrate the assets of Theralink Technologies into its operations.
- The company will seek stockholder approval for the issuance of securities related to the Series C preferred stock and warrants.
- The company will continue to address its internal control weaknesses.
Key Dates
| Date | Description |
|---|---|
| 2018-05-31 | The company's 2018 Incentive Compensation Plan was approved. |
| 2021-04-15 | The company received notification from Covent Bridge Group regarding overpayment. |
| 2023-05-19 | The company granted 10,000 RSUs to Board members. |
| 2023-07-25 | The company entered into a securities purchase agreement for the sale of preferred stock and warrants. |
| 2023-09-07 | The company implemented a 1-for-30 reverse stock split. |
| 2023-12-20 | The company entered into a letter agreement for the sale of additional convertible preferred stock. |
| 2023-12-27 | The company issued 10,000 common shares to Board members. |
| 2024-04-10 | The company entered into a securities purchase agreement for the sale of Series C-2 convertible preferred stock and warrants. |
| 2024-04-11 | The company entered into exchange agreements with holders of Series B preferred stock and warrants. |
| 2024-04-11 | The company entered into a credit agreement with Theralink. |
| 2024-04-30 | The company entered into securities purchase agreements for the sale of Series D convertible preferred stock. |
| 2024-05-01 | The company entered into a settlement and release agreement with Theralink. |
| 2024-05-06 | The company terminated the merger agreement with Theralink. |
| 2024-05-15 | The company had 1,148,321 shares of common stock outstanding. |
Keywords
discontinued operations, strategic shift, preferred stock, warrants, merger, acquisition, working capital deficit, net loss, Theralink Technologies, capital raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.